Sustainability Report

Overview

The report describes Yuhan Corporation's record 2024 consolidated net sales of KRW 2.0678 trillion and the successful U.S. FDA and European EMA approvals of lazertinib, strengthening its global pharmaceutical position. It also presents a company-wide ESG governance structure with a Board-level ESG Committee. The report establishes a 2050 net-zero roadmap, including a 42% GHG reduction target by 2030 from a 2020 base year.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2025
Period: 1 January 2024 – 31 December 2024
Language: English
Pages
File size
Restatement: Disclosed

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Materiality

Assessment
Basis
Matrix

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services